Roflumilast Topical (Zoryve)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

Adverse effects

Mechanism of action

More general terms

References

  1. Brunk D Roflumilast Cream 0.15% Approved for Eczema in Patients Aged 6 or Older. Medscape, July 10, 2024 https://www.medscape.com/viewarticle/roflumilast-cream-approved-eczema-patients-2024a1000cpx
  2. Jump up to: 2.0 2.1 Gooderham MJ, Alonso-Llamazares J, Bagel J et al Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2025 May 7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/40332898 https://jamanetwork.com/journals/jamadermatology/fullarticle/2833460